SCHEMBL4290148

SCHEMBL4290148

CN1CCN(c2ccc(C(=O)O)cc2[N+](=O)[O-])CC1

nearest known ligand 0.78

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.73
LMNA P02545 3/20 0.73
MAPT P10636 5/20 0.71
MAPK1 P28482 2/20 0.71
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
GFER P55789 1/20 0.68
ALDH1A1 P00352 4/20 0.61
GAA P10253 4/20 0.61
L3MBTL1 Q9Y468 2/20 0.59
PKM P14618 2/20 0.58
KDM4E B2RXH2 1/20 0.57
POLB P06746 1/20 0.57
CTPS1 P17812 1/20 0.56
HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4284845 0.99 SMN1; SMN2 (0.71) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL29994344 0.89 ALDH1A1 (0.60) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL17287401 0.89 ALDH1A1 (0.60) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL5211922 0.88 ALDH1A1 (0.76) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL2773960 0.87 ALDH1A1 (0.74) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL31380218 0.87 ALDH1A1 (0.74) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL11456145 0.87 SMN1; SMN2 (0.82) SMN1; SMN2LMNAMAPTMAPK1MEN1
Hydrochloric Acid SCHEMBL11726620 0.86 SMN1; SMN2 (0.80) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL2775026 0.86 ALDH1A1 (0.77) SMN1; SMN2LMNAMAPTMAPK1MEN1
SCHEMBL29805521 0.86 ALDH1A1 (0.77) SMN1; SMN2LMNAMAPTMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928457-B1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A ST EUROPEO DI ONCOLOGIA S R L (IT) 2020-08-12 EP disclosed
US-20150315126-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2015-11-05 US disclosed
EP-2928457-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A Istituto Europeo di Oncologia S.r.l. (IT) 2015-10-14 EP disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
WO-2014086790-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2014-06-12 WO disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
EP-1363925-B1 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2006-11-15 EP disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 US disclosed
CN-1492874-A Macrolide antibiotics 2004-04-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 SMN1; SMN2 4419/4885LMNA 2859/4885MAPT 2911/4885
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 SMN1; SMN2 3554/4885LMNA 1672/4885MAPT 3557/4885
US-20150315126-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A KDM1A, KDM1B, KDM2A SMN1; SMN2 2921/4885LMNA 3215/4885MAPT 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.